Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation

Clinical Transplantation

Volumn 11, Issue 1, 1997, Pages 60-65

  Guckelberger, Olaf ^a   Bechsteln, Wolf O ^a   Neuhaus, Ruth ^a   Luesebrink, Rainer ^a   Lemmens, Hans P ^a   Kratschmer, Bernd ^a   Jonas, Sven ^a   Neuhaus, Peter L ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Diabetes mellitus; Follow up studies; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Immunosuppression; Liver transplantation; Obesity; Survival hypertension

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; PREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031018807     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.1997.tb00782.x     Document Type: Article

References (30)

1. HAAGSMA EB, KLOMPMAKER IJ, VERWER R, SLOOFF MJH. Long-term results after liver transplantation in adults. Scand J Gastroenterol 1991: 26 Suppl 188: 38.
2. KASISKE BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988: 84: 985.
3. MAHONEY JF. Long-term results and complications of transplantation: the kidney. Transpl Proc 1989: 21: 1433.
4. BALLANTYNE CMN, PODET EJ, PATSCH WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. J Am Med Assoc 1989: 262: 53.
5. RAINE AEG. Cardiovascular complications after renal transplantation. In: Morris PJ, ed. Kidney Transplantation. pp. 575-601. Philadelphia: Saunders, 1988.
6. FRIEDMAN EA, SHYH TP, BEYER MM, MANIS T, BUTT KMH. Post-transplant diabetes in kidney transplant recipients. Am J Nephrol 1985: 5: 196.
7. PALMER M, SCHAFFNER F, THUNG SN. Excessive weight gain after liver transplantation. Transplantation 1991: 51: 797.
8. MCDIARMID SV, GORNBEIN JA, FORTUNAT M, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992: 53: 109.
9. HYAMS JS, TREEM WR, ANDREWS WS, HERBERT PN. Lipid abnormalities in pediatric hepatic allograft recipients. J Pediatr Gastroenterol Nutr 1989: 9: 441.
10. MUNOZ SJ, DEEMS RO, MORITZ MJ, MARTIN P, JARRELL BE, MADDREY WC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transpl Proc 1991: 23: 1480.
11. TABASCO-MINGUILLAN J, MIELES L, CARROLL P, et al. Long-term insulin requirement after liver transplantation with FK 506 in american veterans. Transpl Proc 1993: 25: 677.
12. TABASCO-MINGUILLAN J, MIELES L, CARROLL P, et al. Insulin requirements after liver transplantation and FK 506 immunosuppression. Transplantation 1993: 56: 862.
13. GRANT D, WALL W, DUFF J, STILLER C, GHENT C, KEOWN P. Adverse effects of cyclosporine therapy following liver transplantation. Transpl Proc 1987: 19: 3463.
14. FUNG JJ, ALESSIANI M, ABU-ELMAGD K, et al. Adverse effects associated with the use of FK 506. Transpl Proc 1991: 23: 3105.
15. BODENMANN A, ACKRRMANN-LIEBRITCH U. Prävalenz kardiovaskulärer Risikofaktoren in der baselstädtischen Bevölkerung 1989-1990. Schweiz Med Wschr 1993: 123 Suppl 48: 38.
16. NELSON AM, CONN DL. Glucocorticoids in rheumatic disease. Mayo Clin Proc 1980: 55: 758.
17. KAHAN BD, FLECHNER SM, LORBER MI, JENSEN C, GOLDEN D, VANBUREN CT. Complications of cyclosporine therapy. World J Surg 1986: 10: 348.
18. ALESSIANI M, CILLO U, FUNG JJ, et al. Adverse effects of FK 506 overdosage after liver transplantation. Transpl Proc 1993: 25: 628.
19. NEUHAUS P, BLUMHARDT G, BECHSTEIN WO, et al. Comparison of FK 506- and cyclosporine-based immunosuppression in primary orthotoptc liver transplantation. A single-center experience. Transplantation 1995: 59: 31.
20. MCDIARMID SV, COLONNA JO II, SHAKED A, AMENT ME, BUSUTTIL RW. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993: 56: 847.
21. SCANTLEBURY V, SHAPIRO R, FUNG JJ, et al. New onset of diabetes in FK 506 vs. cyclosporine-treated kidney transplant recipients. Transpl Proc 1991: 23: 3169.
22. THE US MULTICENTRE FK506 LIVER STUDY GROUP. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994: 331: 1110.
23. THE EUROPEAN FK506 MULTICENTRE LIVER STUDY GROUP. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994: 344: 423.
24. BISMUTH H. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transpl Proc 1995: 27: 45.
25. THE EUROPEAN FK506 MULTICENTRE LIVER STUDY GROUP. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. Transpl Proc 1994: 26: 3260.
26. MUELLER AR, PLATZ KP, BECHSTEIN WO, et al. Neurotoxicity after orthotopic liver transplantation. Transplantation 1994: 58: 155.
27. PLATZ KP, MUELLER AR, BLUMHARDT G, et al. Nephrotoxicity following orthotopic liver transplantation Transplantation 1994: 58: 170.
28. STEINMÜLLER TM, GRAF KJ, SCHLEICHER J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994: 58: 669.
29. ABOULJOUD MS, LEVY MF, KLINTMALM GB. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine a US multicentre trial. Transpl Proc 1995: 27: 1121.
30. PLATZ KP, MUELLER AR, BECHSTEIN WO, BLUMHARDT G, NEUHAUS P. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. Transpl Proc 1994: 26: 3133.